Babar Ghias - Jul 24, 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: CFO & Head of Corp Development
Signature: /s/ Alane P. Barnes, by power of attorney
Stock symbol: BCRX
Transactions as of: Jul 24, 2025
Transactions value $: $0
Form type: 4
Date filed: 7/28/2025, 04:09 PM
Previous filing: Jul 11, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ghias Babar	CFO & Head of Corp Development	4505 EMPEROR BLVD., SUITE 200, DURHAM	/s/ Alane P. Barnes, by power of attorney	2025-07-28	0002076862

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award	$0	+147K		$0.00	147K	Jul 24, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Award	$0	+305K		$0.00	305K	Jul 24, 2025	Common Stock	305K	$8.55	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2	Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.